๐ฌDeep Research
ALT โ Altimmune Inc ยท catalysts, narrative & risks
Altimmune Inc. (NASDAQ: ALT) โ Research Snapshot (as of 2026-10-04)
Company Baseline
Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, a dual glucagon/GLP-1 receptor agonist, across three liver-disease indications: metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). It generates essentially no product revenue, so its value is tied to clinical, regulatory, and financing milestones rather than commercial sales [9], [10], [11], [12]. Market cap was ~$556.3 million and the stock traded around $3.00 as of late 2026 [9].
AI-assisted research from the K3vl4r desk โ not personalized investment advice. More research โ